137 related articles for article (PubMed ID: 28158470)
1. Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.
Tam VH; Chang KT; Zhou J; Ledesma KR; Phe K; Gao S; Van Bambeke F; Sánchez-Díaz AM; Zamorano L; Oliver A; Cantón R
J Antimicrob Chemother; 2017 May; 72(5):1421-1428. PubMed ID: 28158470
[TBL] [Abstract][Full Text] [Related]
2. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.
Tam VH; Schilling AN; Neshat S; Poole K; Melnick DA; Coyle EA
Antimicrob Agents Chemother; 2005 Dec; 49(12):4920-7. PubMed ID: 16304153
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.
Sy SK; Zhuang L; Beaudoin ME; Kircher P; Tabosa MA; Cavalcanti NC; Grunwitz C; Pieper S; Schuck VJ; Nichols WW; Derendorf H
J Antimicrob Chemother; 2017 Apr; 72(4):1109-1117. PubMed ID: 28077672
[TBL] [Abstract][Full Text] [Related]
4. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
[TBL] [Abstract][Full Text] [Related]
5. Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa.
Tam VH; Schilling AN; Melnick DA; Coyle EA
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):145-51. PubMed ID: 15964503
[TBL] [Abstract][Full Text] [Related]
6. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.
Kuti JL; Horowitz S; Nightingale CH; Nicolau DP
Pharmacotherapy; 2005 Jul; 25(7):935-41. PubMed ID: 16006272
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase Inhibitor.
Ambrose PG; VanScoy BD; Trang M; McCauley-Miller J; Conde H; Bhavnani SM; Alexander DC; Friedrich LV
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947474
[TBL] [Abstract][Full Text] [Related]
8. β-Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill.
Wong G; Taccone F; Villois P; Scheetz MH; Rhodes NJ; Briscoe S; McWhinney B; Nunez-Nunez M; Ungerer J; Lipman J; Roberts JA
J Antimicrob Chemother; 2020 Feb; 75(2):429-433. PubMed ID: 31665353
[TBL] [Abstract][Full Text] [Related]
9. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase.
Kang CI; Pai H; Kim SH; Kim HB; Kim EC; Oh MD; Choe KW
J Antimicrob Chemother; 2004 Dec; 54(6):1130-3. PubMed ID: 15486080
[TBL] [Abstract][Full Text] [Related]
10.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
11. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
[TBL] [Abstract][Full Text] [Related]
12. Rapid detection of antibiotic resistance by MALDI-TOF mass spectrometry using a novel direct-on-target microdroplet growth assay.
Idelevich EA; Sparbier K; Kostrzewa M; Becker K
Clin Microbiol Infect; 2018 Jul; 24(7):738-743. PubMed ID: 29079147
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
14. Application of Pharmacodynamic Profiling for the Selection of Optimal β-lactam Regimens in a Large University Hospital.
Koomanachai P; Yungyuen T; Disthaporn P; Kiratisin P; Nicolau DP
Int J Infect Dis; 2016 May; 46():22-6. PubMed ID: 27021531
[TBL] [Abstract][Full Text] [Related]
15. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
[TBL] [Abstract][Full Text] [Related]
16. Development of Antibiotic Resistance during Simulated Treatment of Pseudomonas aeruginosa in Chemostats.
Feng Y; Hodiamont CJ; van Hest RM; Brul S; Schultsz C; Ter Kuile BH
PLoS One; 2016; 11(2):e0149310. PubMed ID: 26872140
[TBL] [Abstract][Full Text] [Related]
17. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
18. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
[TBL] [Abstract][Full Text] [Related]
20. In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates.
Sutherland CA; Verastegui JE; Nicolau DP
Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):39. PubMed ID: 27316973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
